JP2024541533A5 - - Google Patents

Info

Publication number
JP2024541533A5
JP2024541533A5 JP2024531423A JP2024531423A JP2024541533A5 JP 2024541533 A5 JP2024541533 A5 JP 2024541533A5 JP 2024531423 A JP2024531423 A JP 2024531423A JP 2024531423 A JP2024531423 A JP 2024531423A JP 2024541533 A5 JP2024541533 A5 JP 2024541533A5
Authority
JP
Japan
Prior art keywords
oxy
pyran
cancer
tetrahydro
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541533A (ja
Filing date
Publication date
Priority claimed from PCT/CN2021/133429 external-priority patent/WO2022111621A1/en
Application filed filed Critical
Publication of JP2024541533A publication Critical patent/JP2024541533A/ja
Publication of JP2024541533A5 publication Critical patent/JP2024541533A5/ja
Pending legal-status Critical Current

Links

JP2024531423A 2020-11-27 2022-11-23 アミノヘテロアリールキナーゼ阻害薬 Pending JP2024541533A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020132454 2020-11-27
CN2021081236 2021-03-17
PCT/CN2021/133429 WO2022111621A1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors
CNPCT/CN2021/133429 2021-11-26
PCT/CN2022/133770 WO2023093769A1 (en) 2020-11-27 2022-11-23 Aminoheteroaryl kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2024541533A JP2024541533A (ja) 2024-11-08
JP2024541533A5 true JP2024541533A5 (cg-RX-API-DMAC10.html) 2025-11-28

Family

ID=81753779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023531615A Active JP7895947B2 (ja) 2020-11-27 2021-11-26 アミノヘテロアリールキナーゼ阻害剤
JP2024531423A Pending JP2024541533A (ja) 2020-11-27 2022-11-23 アミノヘテロアリールキナーゼ阻害薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023531615A Active JP7895947B2 (ja) 2020-11-27 2021-11-26 アミノヘテロアリールキナーゼ阻害剤

Country Status (10)

Country Link
US (2) US20240166635A1 (cg-RX-API-DMAC10.html)
EP (2) EP4251613A4 (cg-RX-API-DMAC10.html)
JP (2) JP7895947B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230127228A (cg-RX-API-DMAC10.html)
CN (3) CN122483000A (cg-RX-API-DMAC10.html)
AU (3) AU2021385745C1 (cg-RX-API-DMAC10.html)
CA (2) CA3202990A1 (cg-RX-API-DMAC10.html)
IL (1) IL303237A (cg-RX-API-DMAC10.html)
MX (1) MX2024006300A (cg-RX-API-DMAC10.html)
WO (2) WO2022111621A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor
CN119343333A (zh) * 2022-05-27 2025-01-21 安锐生物医药公司 氨基杂芳基激酶抑制剂
WO2025006400A1 (en) * 2023-06-25 2025-01-02 Allorion Therapeutics Inc Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
EP4725942A1 (en) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Compounds active on cyclin d1 pathway and their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
IL159120A0 (en) * 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HUP0402245A3 (en) * 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
AU2007338792B2 (en) * 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2142550A1 (en) * 2007-04-02 2010-01-13 Palau Pharma, S.A. Pyrrolopyrimidine derivatives as jak3 inhibitors
MX2009011199A (es) 2007-04-16 2010-03-17 Hutchison Medipharma Entpr Ltd Derivados de pirimidina.
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
TW201024281A (en) * 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN110386901B (zh) 2018-04-23 2022-11-25 上海医药工业研究院 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US11919904B2 (en) * 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
JP2023515629A (ja) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Cdk2/4/6阻害剤としての化合物
WO2022096473A1 (en) * 2020-11-04 2022-05-12 Umicore A positive electrode active material for rechargeable batteries
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor

Similar Documents

Publication Publication Date Title
CN111201223B (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
JP6524221B2 (ja) Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2022058514A (ja) メニン-mll相互作用の阻害剤
CN115947681B (zh) 整合应激通路的调节剂
JP5852678B2 (ja) 抗腫瘍剤の効果増強剤
JP2024023295A (ja) Shp2の活性を阻害するための化合物の製造方法
TWI609012B (zh) 氨基喹唑啉類衍生物及其鹽和使用方法
TWI693220B (zh) 1,3,4-噻二唑化合物及其用於治療癌症之用途
JP2023533938A5 (cg-RX-API-DMAC10.html)
CN113993591A (zh) 新egfr抑制剂
JP2020090535A (ja) 癌の処置のためのウリジンのジオキソラン類似体
TWI448461B (zh) 4-aniline-6-butenamide-7-alkyl ether quinazoline derivatives, methods and uses thereof
US20160175284A1 (en) Estrogen receptor modulators and uses thereof
RU2770824C2 (ru) Противоопухолевый агент
CN111643496A (zh) 使用mek抑制剂的方法
JP6549115B2 (ja) 新規抗癌剤
TW201936585A (zh) 5-氟尿嘧啶化合物
TW202114985A (zh) Ep拮抗劑
WO2023093769A1 (en) Aminoheteroaryl kinase inhibitors
JP4852605B2 (ja) 放射線治療増強剤
RU2483064C2 (ru) Твердые формы ингибитора raf-киназы
JP2024515061A5 (cg-RX-API-DMAC10.html)
US20250345339A1 (en) Doses and regimens of her2 inhibitors
JP7733273B2 (ja) G12d変異kras阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
WO2021025976A1 (en) Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same